Skip to main content
PLOS One logoLink to PLOS One
. 2026 Apr 20;21(4):e0346420. doi: 10.1371/journal.pone.0346420

Who would take part in a pandemic preparedness cohort study? The role of vaccine-related affective polarisation: Cross-sectional survey

Aziz Mert Ipekci 1,2,3, Eva Maria Hodel 1,3, Maximilian Filsinger 3,4,5, Selina Wegmüller 3,6,7, Simone Schuller 3,8, Markus Freitag 3,5, Annika Frahsa 1,3, Gilles Wandeler 3,9, Nicola Low 1,3,*
Editor: Angelo Moretti10
PMCID: PMC13095020  PMID: 42008431

Abstract

Cohort studies are an important tool for public health research about emerging infectious diseases. Willingness to participate in research is associated with multiple factors. Little is known about the role of people’s feelings, especially in the aftermath of the COVID-19 pandemic. Affective polarisation, an affinity for people with similar attitudes to oneself and hostility toward those with opposing views, is a measure of feelings about issues, including COVID-19 vaccination. The aim of this study was to investigate factors associated with willingness to participate in a future household-based cohort study on pandemic preparedness. We did a cross-sectional online survey in the Canton of Bern, Switzerland. We invited a random sample of persons aged 18 + years from 15,000 private households. We asked about willingness to take part and collected data about demographic, social and household characteristics, and affective polarisation related to COVID-19 vaccination. We performed univariable and multivariable analyses, weighted by household size to estimate odds ratios (with 95% confidence intervals, CI). Among responders, 49.8% (95% CI 47.9–51.8, weighted proportion) were willing to take part in a cohort study. In multivariable analysis, higher educational level (adjusted odds ratio 2.48, 95% CI 1.81–3.39) and higher monthly income (1.92, 1.39–2.65) were most strongly associated with higher willingness to participate. Opposition to COVID-19 vaccination was associated with lower willingness to participate (0.53, 0.39–0.72). Affective polarisation modified the relationship between vaccination attitudes and willingness to participate. Compared with non-polarised vaccination supporters, polarised supporters were more willing to participate (marginal adjusted odds ratio 1.51, 1.05–2.16), whereas willingness to participate was lower among both non-polarised (0.53, 0.32–0.86) and affectively polarised (0.26, 0.12–0.56) vaccination opposers. Willingness to participate in a cohort study was moderate. Following the COVID-19 pandemic, addressing affective polarisation, as well as socioeconomic factors, is needed to improve participation in pandemic preparedness research.

Introduction

Cohort studies are an important tool for public health research about emerging infectious diseases and pandemics [1]. At the start of the COVID-19 pandemic in early 2020, policy makers needed to know the proportion of the population who had already been exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to plan appropriate prevention measures. Researchers in Switzerland were among the first to provide this information, by contacting participants in an existing cohort study on non-communicable diseases and obtaining blood samples for SARS-CoV-2 antibody testing [2]. Seroprevalence was 10%, showing that most people were still susceptible to SARS-CoV-2, guiding the need for ongoing measures to prevent transmission in the population with the minimum of restrictions [2]. In anticipation of the next pandemic, global health experts have proposed that ‘pandemic preparedness cohorts’ can establish the research infrastructure and then pivot quickly to collect relevant data when a new pandemic pathogen starts to spread [1]. New cohort studies in this field are needed because existing studies, established for other reasons, have not necessarily collected the data needed to improve understanding about behaviours and exposures associated with susceptibility, transmission and immunity of emerging pandemic pathogens.

People’s feelings and concerns about public health issues may influence their willingness to participate in research in a new field and should be considered when designing and starting studies [3]. Documented reasons for longstanding declines in participation in population-based research include limited time, declines in altruism and community involvement in general, and mistrust in science [4]. Previous studies have focused on socioeconomic and demographic factors associated with willingness to participate in health research, and on views about issues such as data privacy [46]. The novelty and scale of the COVID-19 pandemic may now have affected attitudes towards research because of the unprecedented amounts of new research findings [7], awareness about research [8], and uncertainties about communication, and public trust between scientists, policymakers and the public [911]. Political polarisation, according to ideology, partisan affiliation or trust in political institutions, has characterised responses to many aspects of COVID-19 prevention [12,13]. The concept of affective polarisation, defined as an affinity for people with similar attitudes to oneself and hostility toward those with opposing views, has been used as a quantitative method to capture peoples’ emotions about the opinions of others [14]. Whilst affective polarisation was first defined and studied in the United States of America to understand political opinions [14], the COVID-19 pandemic revealed associations between affective polarisation and health behaviours such as COVID-19 vaccination uptake, adherence to pandemic countermeasures or anxiety about COVID-19 [1418]. Measures of people’s feelings about public health measures such as COVID-19 vaccination, and how they view others, are more proximate to health-associated behaviours than partisan or ideological differences. Whether affective polarisation is associated with willingness to take part in research about pandemics more generally is not well understood. The objectives of this study were: 1) to investigate sociodemographic factors associated with willingness to participate in a planned pandemic preparedness cohort study; 2) to explore associations between COVID-19 vaccination-related affective polarisation and willingness to participate; and 3) to describe reasons for taking part, or not taking part, in a pandemic preparedness cohort study.

Materials and methods

We did a cross-sectional survey in the canton of Bern, Switzerland. Bern, population 1,070,898, is the largest of the 26 Swiss cantons geographically, with demographic characteristics similar to those of Switzerland as a whole. The survey was part of the preparation for a population-based pandemic preparedness cohort study, BEready (“Bern, get ready”). The BEready cohort will study whole households [19], including pets [20], because of the importance of within household transmission of infectious agents [21] and a One Health approach to understand and prepare for pandemics which may spread between humans and animals [22]. The Cantonal Ethics Committee in Bern provided an exemption from ethical approval under the Human Research Act because the survey did not ask for any personal health-related information (BASEC-Nr: Req-2022–00877). We report this study following the Strengthening the Reporting of Observational Studies in Epidemiology guideline for cross-sectional studies (research checklist) (S1 Table).

Study sample

We contacted the Cantonal Administration and Information Office to obtain a random sample of private household addresses in the canton of Bern. The requested sample of 15,000 households was the same as that of a previous online study about willingness to participate in personalised health research in Switzerland [5]. We requested a random sample of 3,000 households, each with 1, 2, 3, 4, or 5 + members, oversampling larger households because their participation is important for a cohort study that aims to investigate household infection transmission. One person aged 18 or older from each household was randomly chosen as the primary contact. The selected household members received a letter by surface mail, which introduced the issue of pandemic preparedness and about potential participation in research about existing and future infectious diseases. The letter contained a personal access code and a link to an online questionnaire. On request, they could receive a printed version of the survey. They were informed that by filling in the questionnaire, they consented to participate in the study. Invitation letters were sent on 19th September 2022, with two reminders on 14th October and 9th November 2022. The survey closed on 18th December 2022.

Survey development

The survey questions were taken from published national and international questionnaires, whenever possible, including the Swiss Health Study pilot [23], a nationwide survey about personalised health research [24], the COVID-19 social mixing survey [25], the International Social Survey Programme [26] and a study of COVID-19-associated affective polarisation [15]. The survey was available in German, French, Italian, and English. A convenience sample of 10 people speaking the languages of the survey tested the questions and we made changes to improve readability where necessary.

The primary outcome was self-reported willingness to participate in a long-term cohort study about infectious diseases, measured on a 4-point scale, “yes”, “probably yes”, “probably no”, or “no”. The survey questions covered: demographic characteristics including age and gender identity, social, and household characteristics, patterns of social mixing and a pre-defined list of motivations to participate or not participate in cohort studies (S2 Table). Opinions about COVID-19 vaccination were measured on a scale from zero (complete rejection) to 10 (complete support). We measured affective polarisation using a feeling thermometer [27]. First, we asked participants about their feelings towards people who get vaccinated from –5 (“very cold”) to +5 (“very warm”). Then, we asked the same question about people who do not get vaccinated. The absolute difference between their answers to the two questions gave the affective polarisation level on a scale from zero to ten [15].

Patient and public involvement

We did not involve patients or the public in the development of the questionnaire used in this study. After the survey was completed, we put together a community advisory group of representatives and members of the public, who reviewed the study findings. Their feedback is informing community engagement strategies to optimise enrolment into the BEready cohort study.

Statistical analysis

We used RStudio for all analyses [28]. To account for the oversampling of larger households, we performed inverse probability weighting (S3 Table) using the survey package (version 4.4–2) [29]. We defined respondents as those who answered at least half of the survey questions [5] and included respondents who answered the question about the primary outcome in statistical analyses. We compared responders and non-responders, based on the two variables available, household size and main language spoken at home. We used the municipality of residence to map the proportions of responders willing to participate. We dichotomised three variables (S2 Table, S1 Fig): 1) the primary outcome variable, willingness to participate (yes/no), combining responses “yes” and “probably yes”, and “no” and “probably no”; 2) opinion about vaccination (opposition, 0–4, support, 6–10). A response of 5 was considered as neutral and was treated as missing in the main analysis [15]; affective polarisation (not polarised, 0–4, polarised, 5–10). We grouped variables such as education and income into a smaller number of categories, following conventions used in previous publications (S2 Table) [25].

We described our study population characteristics using means (and standard deviation, SD) or median (and interquartile range, IQR) for continuous variables and frequencies and percentages for categorical variables. We used logistic regression to estimate univariable odds ratios (OR and 95% confidence intervals, CI) for the association between reported willingness to participate and exposure variables. We built a multivariable regression model, based on knowledge available on the topic and findings from the univariable analyses. The model included age, gender, education, current work situation, nationality, household income, household size, location, language, opinion about COVID-19 vaccination, and vaccination-related polarisation. We compared models using likelihood ratio tests and expressed associations as adjusted odds ratios, aOR, with 95% CI. To explore affective polarisation related to opinions about COVID-19 vaccination further, we examined the observed association between respondents’ support or opposition to COVID-19 vaccination and willingness to participate, according to the presence or absence of affective polarisation. We included an interaction term in the multivariable model and reported marginal odds ratios [30]. Lastly, we summarised motivations for participation or non-participation in a cohort study. Participants could choose multiple reasons.

We conducted three sensitivity analyses: 1) we reclassified people with a score of 5 in the vaccination opinion scale with either supporters of vaccination or as opposing vaccination; 2) we tested alternative cut-off points for affective polarisation (not polarised, 0–3; polarised, 4–6; heavily polarised, 7–10); 3) we varied the definition of a responder by adjusting the minimum number of answered survey questions required for inclusion (33% and 66% considered as responders).

Results

Characteristics of the study population

The 15,000 selected households came from 306/335 municipalities in the Canton of Bern. Overall, 3,425/15,000 (22.8%) people from 273 municipalities responded to at least half of the survey and 3,394 (22.6%) responders replied to the question about willingness to participate in a cohort study (S2 Fig). The highest proportion of responders were from 2-person households (29.2%, 877/3,000), with the lowest proportion from households with 5 or more members (11.7%, 351/3,000) (S4 Table). The distribution of respondents, according to the main language spoken in the household, was similar to the numbers invited (S4 Table). Responses were similar among German-speaking (22.8%, 3,074/13,474) and French-speaking households (21.2%, 312/1,473). Among the remaining households, there were 18.2% (2/11) Italian-speaking and 14.6% (6/41) English-speaking respondents. The percentage of missing values was 0.5% to 4.1% for sociodemographic variables. For the questions related to COVID-19 vaccine, 8.5% and 11.8% did not respond. We did not conduct imputation for missing values.

We present results from the weighted analysis; descriptive results in the unweighted analysis were very similar (S5 Table). Table 1 presents the weighted distribution of the participants’ characteristics. Amongst responders, there were more women (256,277, 52.3%) than men (229,354, 46.8%), more than a third (182,256, 37.2%) had tertiary education and two-fifths had a household income between 4,500–9,000 Swiss Francs (205,540, 42.0%).

Table 1. Self-reported willingness to participate in a long-term study about infectious diseases, weighted denominator.

Denominator N1
Willingness to participate in cohort study,
% (95% confidence intervals)
Number of people 489,973 (100%) 49.8 (47.9 - 51.8)
Age group, years 18-29 44,522 (9.1%) 58.5 (52.9 - 64.0)
30-64 291,949 (59.6%) 52.5 (50.0 - 54.9)
64+ 153,501 (31.3%) 42.2 (38.5 - 46.0)
Gender Female 256,277 (52.3%) 50.5 (47.8 - 53.2)
Male 229,354 (46.8%) 49.2 (46.4 - 52.1)
Other 1,854 (0.4%) 58.7 (27.2 - 85.8)
No response 2,488 (0.5%) 25.2 (5.1 - 58.4)
Education level Compulsory education or less 69,135 (14.1%) 31.1 (26.5 - 36.0)
Upper secondary 225,091 (46.0%) 46.0 (43.1 - 48.9)
Tertiary 182,256 (37.2%) 62.6 (59.5 - 65.6)
Other 4,752 (1.0%) 43.9 (23.1 - 66.4)
No response 8,740 (1.8%) 33.2 (20.3 - 48.2)
Current work situation Full-time employee 211,250 (43.1%) 54.9 (51.9 - 57.9)
Part-time employee 97,113 (19.8%) 55.5 (51.5 - 59.5)
Not employed 151,874 (31.0%) 41.0 (37.3 - 44.7)
In education 10,546 (2.2%) 60.7 (51.3 - 69.6)
Other 6,523 (1.3%) 32.1 (18.7 - 48.0)
No response 12,666 (2.6%) 27.4 (17.3 - 39.3)
Income, Swiss Francs <4,500 96,560 (19.7%) 43.6 (38.7 - 48.5)
4,500–9,000 205,540 (42.0%) 51.6 (48.5 - 54.6)
>9,000 105,130 (21.5%) 64.9 (61.3 - 68.5)
Other 62,679 (12.8%) 32.7 (27.9 - 37.7)
No response 20,064 (4.1%) 26.9 (19.0 - 35.8)
Household residents, number 1 185,820 (38.0%) 52.6 (48.7 - 56.4)
2 170,629 (34.8%) 48.2 (45.0 - 51.5)
3 54,814 (11.2%) 51.1 (47.6 - 54.7)
4 53,981 (11.0%) 48.5 (45.1 - 51.8)
5+ 24,729 (5.0%) 40.5 (35.7 - 45.3)
Household location 2 Urban 278,236 (56.9%) 52.3 (49.6 - 55.0)
Intermediate 118,778 (24.5%) 48.4 (44.6 - 52.3)
Rural 90,725 (18.5%) 44.3 (40.0 - 48.7)
Nationality Swiss 415,354 (84.8%) 50.8 (48.6 - 52.9)
Foreign 69,632 (14.2%) 45.7 (41.1 - 50.3)
No response 4,987 (1.0%) 28.0 (13.0 - 47.2)
Language spoken at home German 428,396 (87.4%) 51.1 (48.9 - 53.3)
French 45,301 (9.2%) 49.6 (43.2 - 55.9)
Italian 6,604 (1.4%) 49.4 (32.4 - 66.5)
English 9,671 (2.0%) 54.2 (42.5 - 65.6)
Opinion about vaccination 3 For vaccination 322,536 (65.8%) 57.7 (55.3 - 60.1)
Oppose vaccination 83,395 (17.0%) 32.6 (28.4 - 36.9)
No response 41,576 (8.5%) 33.3 (27.3 - 39.7)
Vaccination related affective polarisation Polarised 244,371 (49.9%) 56.8 (54.0 - 59.5)
Not polarised 187,844 (38.3%) 44.6 (41.5 - 47.6)
No response 57,758 (11.8%) 37.6 (32.3 - 43.1)
Willingness to participate with children
Number with children Willingness to participate
On behalf of their children 80,605 (100%) 40.0 (37.0 - 42.9)
Willingness to participate with pets
Number with pets Willingness to participate
On behalf of their pets Any pet 134,046 (100%) 46.1 (42.6 - 49.6)
Type of pet 4 Dogs 43,521 (32.5%) 47.9 (41.8 - 54.1)
Cats 90,996 (67.9%) 46.0 (41.7 - 50.3)
Rabbits 7,066 (5.3%) 37.9 (26.9 - 49.9)
Rodents 6,686 (5.0%) 58.6 (45.2 - 71.2)
Others 13,575 (10.1%) 47.8 (37.6 - 58.0)

1Weighted number of participants

2The sum of percentages for the household location variable does not equal 100% due to missing data that were not classified by the Cantonal Administration and Information Office.

3The sum of percentages for the opinions on vaccination does not total 100% because responses marked as “5”, representing a neutral position at the midpoint of the scale, were excluded from the analysis.

4The sum of the percentages exceeds 100% because some households reported owning multiple types of pets.

Sociodemographic factors and willingness to participate in a long-term cohort study

Overall, 1,660/3,394 (unweighted proportion 48.9%, weighted proportion 49.8%, 95% CI 47.9–51.8) of responders reported being willing to participate in a long-term study. Willingness to participate was higher near the city of Bern than in rural areas (Table 1, Fig 1). The highest levels of willingness were among individuals with tertiary education (weighted proportion 62.6%) and those earning more than 9,000 Swiss Francs per month (64.9%). The lowest levels were seen among individuals with less than compulsory education (31.1%) and those categorised as being opposed to COVID-19 vaccination (32.6%). Similar proportions of women and men were willing to participate. We asked respondents whether they would be willing for their children and pets to participate in a long-term study (Table 1). Among respondents with children, the willingness for their children to participate was lower (40.0%) than for themselves (49.8%). Among those with pets, willingness to include pets varied by species, with the highest participation rates for rodents (58.6%), followed by dogs (47.9%), cats (46.0%), and rabbits (37.9%).

Fig 1. Proportion of respondents willing to participate, by municipality in the canton of Bern, Switzerland.

Fig 1

The map uses: the swissBOUNDARIES3D dataset and the official directory of towns and cities both published by the Federal Office of Topography swisstopo (swisstopo.admin.ch); and the lakes and rivers 2025 GEOM TK dataset of Swiss Federal Statistical Office (bfs.admin.ch) [31,32].

After adjustment for all variables included in the model, willingness to participate was more likely among participants with the highest educational level (aOR 2.48, 95% CI 1.81–3.39) and those with the highest income (aOR 1.92, 1.39–2.65); and was less likely among older participants (aOR 0.99, 0.98–0.99 for a one-year increase) and larger households (5 or more people vs. 1 person, aOR 0.67, 0.44–1.01) (Table 2).

Table 2. Factors associated with willingness to participate, univariable and multivariable logistic regression.

Univariable model Multivariable model1
Characteristic OR2 (95% CI)2 p-value aOR3 (95% CI)2 p-value
Age, per year 0.99 (0.98 - 0.99) <0.001 0.99 (0.98 - 0.99) <0.001
Gender 0.346 0.165
Female 1 1
Male 0.95 (0.81 - 1.11) 0.9 (0.74 - 1.09)
Other 1.39 (0.39 - 4.93) 3.13 (0.87 - 11.3)
No response 0.33 (0.09 - 1.24) 0.46 (0.06 - 3.33)
Education level <0.001 <0.001
Compulsory education or less 1 1
Upper secondary education 1.89 (1.47 - 2.43) 1.59 (1.19 - 2.12)
Tertiary education 3.70 (2.86 - 4.79) 2.48 (1.81 - 3.39)
Other 1.74 (0.72 - 4.19) 1.57 (0.49 - 5.05)
No response 1.10 (0.57 - 2.12) 1.61 (0.75 - 3.43)
Current work situation <0.001 0.053
Full-time employee 1 1
Part-time employee 1.03 (0.84 - 1.25) 1.28 (0.98 - 1.67)
Not employed 0.57 (0.47 - 0.69) 0.93 (0.70 - 1.23)
In education 1.27 (0.85 - 1.91) 1.91 (1.15 - 3.15)
Other 0.39 (0.20 - 0.77) 0.85 (0.40 - 0.79)
No response 0.31 (0.18 - 0.54) 0.92 (0.49 - 1.76)
Household income, Swiss Francs <0.001 <0.001
< 4’500 1 1
4’500 − 9’000 1.39 (1.11 - 1.75) 1.21 (0.93 - 1.59)
> 9’000 2.40 (1.87 - 3.08) 1.92 (1.39 - 2.65)
Other 0.62 (0.46 - 0.83) 0.62 (0.44 - 0.87)
No response 0.47 (0.29 - 0.75) 0.46 (0.26 - 0.83)
Number of household members 0.002 <0.001
1 1 1
2 0.84 (0.69 - 1.03) 0.74 (0.59 - 0.95)
3 0.94 (0.76 - 1.16) 0.65 (0.50 - 0.85)
4 0.85 (0.69 - 1.04) 0.50 (0.38 - 0.67)
5≤ 0.61 (0.48 - 0.79) 0.67 (0.44 - 1.01)
Household location 0.008 0.601
Urban 1 1 1 1
Intermediate 0.86 (0.71 - 1.03) 1.03 (0.83 - 1.27)
Rural 0.73 (0.59 - 0.89) 0.90 (0.71 - 1.14)
Nationality 0.013 0.791
Swiss 1 1 1 1
Foreign 0.81 (0.66 - 1.00) 0.90 (0.65 - 1.25)
No response 0.38 (0.16 - 0.87) 0.84 (0.30 - 2.31)
Language 0.907 0.729
German 1 1 1 1
French 0.99 (0.76 - 1.29) 1.11 (0.80 - 1.54)
Italian 0.99 (0.51 - 1.92) 1.34 (0.70 - 2.53)
English 1.19 (0.74 - 1.92) 0.90 (0.48 - 1.67)
Opinion about COVID-19 vaccination <0.001 <0.001
Support vaccination 1 1 1 1
Oppose vaccination 0.35 (0.28 - 0.44) 0.53 (0.39 - 0.72)
No response 0.37 (0.27 - 0.49) 0.34 (0.07 - 1.69)
Vaccination-related polarisation <0.001 <0.001
Not polarised 1 1 1 1
Polarised 1.64 (1.38 - 1.93) 1.51 (1.20 - 1.89)
No response 0.75 (0.58 - 0.97) 0.88 (0.47 - 1.67)

1Model includes the following variables: Age, gender, education level, current work situation, income, household size, household location, language, nationality, opposition to vaccination, affective polarisation: vaccination opposer (interaction term) and willingness to participate (outcome).

2OR, odds ratio, CI, confidence interval.

3aOR, adjusted odds ratio.

COVID-19 vaccination-related factors and willingness to participate

Most respondents expressed opinions in support of COVID-19 vaccination (65.8%) (Table 1, S1 Fig). In both univariable and multivariable analyses, people who had negative opinions about COVID-19 vaccination were less willing than those who expressed support for vaccination to say they would participate in a long-term cohort study (aOR 0.53, 0.39–0.72). Amongst all respondents, people with polarised feelings towards others about COVID-19 vaccination were more willing than those defined as non-polarised to participate (aOR 1.51, 1.20–1.89) (Table 2). The direction of the association between COVID-19 vaccination opinions and willingness to participate differed between those who showed affective polarisation and those who were non-polarised (Table 3). The increase in willingness to participate among people with polarised opinions was only observed among those who supported COVID-19 vaccination (aOR 1.51, 1.05–2.16). People with opinions opposed to COVID-19 vaccination were less willing to participate than non-polarised supporters of vaccination, particularly those who were affectively polarised (aOR 0.26, 0.12–0.56). The three sensitivity analyses did not change the results (S6 Table).

Table 3. Effect modification by affective polarisation status of the association between opinion about COVID-19 vaccination and willingness to participate.

Affective polarisation status Support vaccination Oppose vaccination
N2 with outcome aOR3 (95% CI) N2 with outcome aOR3 (95% CI)
Not polarised 97,556 1 56,783 0.53 (0.32 - 0.86)
Polarised 216,219 1.51 (1.05 - 2.16) 21,406 0.26 (0.12 - 0.56)

1Adjusted for age, education level, current work situation, income, household size, household location, gender, language spoken, foreign status, polarisation status, vaccine support status

2Weighted number of participants

3Marginal adjusted odds ratio

Reasons for participation or non-participation in research

People who answered “yes”, “probably yes”, and “probably no” to the willingness to participate question were asked about their reasons to participate in a long-term study (n = 2,776). People who answered “no” were asked for reasons to decline participation (n = 637) (S7 Table). The most common reasons for participation were: “I can contribute to the health of fellow human beings” (n = 1,559, 56%); “I can contribute to better preparation for the next pandemic” (n = 1,134, 41%), followed by answers such as, “I am interested in research and health” (n = 1,031, 37%), “I will get a free health check” (n = 713, 26%) and “I will receive the study results as feedback” (n = 682, 25%). The main reasons to decline were: lack of interest (n = 266, 42%); privacy concerns and mistrust (Fig 2, S7 Table).

Fig 2. Reasons for non-participation, amongst 637 respondents who stated that they would not be willing to take part in a cohort study.

Fig 2

Discussion

In this cross-sectional online survey, about half of respondents reported willingness to take part in a long-term cohort study for pandemic preparedness, with slightly lower proportions willing for their children or pets to take part. Older adults, individuals with lower levels of education and income, and those opposing COVID-19 vaccination were less likely to report that they would participate. Affective polarisation was associated with increased willingness to participate among those supporting COVID-19 vaccination, whilst people expressing opposition to vaccination were less willing to participate, particularly those who were affectively polarised. The main reasons given for participation in research were to help others and to improve pandemic preparedness, while lack of interest, privacy concerns and mistrust were the most commonly stated reasons for non-participation.

Strengths and limitations

The design of our study has three main strengths. First, the sample was drawn at random from a population register, with oversampling from larger households, which account for a smaller proportion of households in the canton of Bern. Second, we asked about affective polarisation related to feelings about COVID-19 vaccination, in addition to more traditional sociodemographic factors. Third, we used questions that had been used and/or validated in other surveys to facilitate comparisons with other studies. There are three main limitations to the study design. First, the study participants came from a single canton in Switzerland because this is the setting for the planned BEready cohort study. Whilst this may limit generalisability of the study findings, the demographic characteristics of the canton of Bern are similar to those of Switzerland as a whole. Second, for reasons of efficiency, the questionnaire was primarily designed to be answered online and was available in only four languages. The survey was, therefore, not accessible to people without ready access to a computer and the internet, or to those who could not understand one of the survey languages; only 184 people asked for a paper version of the questionnaire. Our findings may therefore be biased if factors limiting participation to those with digital access are also associated with willingness to participate in research. Third, the number of questions in the survey was restricted since a lengthy questionnaire might have decreased the response rate [33]. Whilst there is evidence that political ideology and trust in government institutions are associated with an individual’s willingness to participate in scientific research [34,35], we were not able to include questions about a broader range of political variables.

Comparison with other studies

Assessments of the level of willingness to participate in public health research need to take into account the proportion responding to the online survey. When compared with other online surveys using random sampling approaches, our study’s response rate (23%) was acceptable in comparison with 2.9% for a survey about precision medicine in South Korea [36], 16% for a pilot study for national cohort study [23] and 34% for a study about personalised health research in Switzerland [5]. We could not assess the extent of non-response bias in detail because only two characteristics were available for comparison; the proportion of responders according to household language, which was similar to that of the sample as a whole, and household size, with people from larger households less likely to respond than those from smaller households.

The proportion of survey participants reporting willingness to participate varies between studies. About 50% of potential participants in our study were willing to participate, which is comparable to findings from studies on personalised health research in Switzerland (54%) [5] and the United States (54%) [37], and clinical research in India (42%) [8]. Similarly, a large European survey involving 32 countries found that 53% of respondents were willing to provide personal information to a biobank [38]. In Australia, a telephone survey found that 61% of respondents were willing to participate in health research in general, with willingness increasing when specific information about the study was provided [39]. In Switzerland, 90% of respondents to an online survey reported willingness to participate in a national health cohort study [6]. The researchers suggested this high proportion could reflect a strong civic duty to support public research, particularly when led by the Federal Office of Public Health [6]. Indeed, altruism was one of the main reasons, stated by 56% of people who said that they would be willing to take part in a cohort study about pandemic preparedness. Willingness to take part in future research might also be overestimated, however, given that they selectively took part in the online survey. Actual participation may also be lower than intended participation. In studies in high-income countries, including ours, younger people, those with higher levels of education and/or higher incomes were more likely to say they would participate. Gender was not strongly associated with willingness to participate; the small number of respondents reporting a non-binary gender makes interpretation uncertain. We did not find any other studies about affective polarisation and willingness to participate in research.

Interpretation of the study findings

Our investigation of affective polarisation as a dimension of willingness to participate in research adds to the knowledge in this field, particularly in the context of designing research that might investigate preventive interventions, such as vaccination against COVID-19. The finding that people who support vaccination were more willing to take part in a long-term cohort study than people who oppose vaccination is in line with general support for research by “good citizens” [3]. The modifying effect of affective polarisation provides additional insight. People who supported COVID-19 vaccination were even more motivated to take part in research if they also held polarised views about other people’s opinions. In contrast, both polarised and non-polarised opponents of vaccination reported lower willingness to participate than non-polarised supporters of vaccination. Existing research provides evidence of a link between affective polarisation and reduced vaccination uptake [40,41], lower concern about COVID-19, and decreased support for COVID-19 policies [42]. These findings align with our study if we consider participation in a long-term cohort study as a health-related behaviour. Additionally, we found that mistrust and concerns about privacy of health data were among the top reasons for unwillingness to participate. We did not examine the association between affective polarisation and trust, but other researchers have found this in relation to vaccination and political opinions [4345].

Implications for research and public health

The findings from our study have implications for public health research and policy making. The strong associations between opinions about COVID-19 vaccination, vaccine-related affective polarisation and willingness to participate in future studies supports a multidisciplinary approach to research and its communication [9]. The relationship between affective polarisation and willingness to participate in public health research should also be extended to different contexts and countries with varying levels of affective polarisation [15] to examine the generalisability of our findings. Strategies to overcome under-representation of people who are older, less well educated, have lower incomes and have more negative opinions about preventive measures in research for pandemic preparedness are also needed to reduce the potential for participation bias. Community engagement activities could raise awareness of the importance of research about infectious diseases and pandemic preparedness and reduce mistrust about sharing health data. Technological advances, which reduce barriers to participation, such as lack of time, including the use of online surveys and mailing of self-collected biological samples might also be beneficial. Policy makers will benefit from future research about potential pandemic threats, despite the difficulties of achieving and sustaining high levels of participation [1]. Our study examined willingness to participate in research after the emergency phase of the COVID-19 pandemic, which might be affected by pandemic fatigue and shifting attitudes to trust. A study in Switzerland found that affective polarisation in relation to COVID-19 vaccination was less marked in 2023 than in 2022 [45]. Longer term study of affective polarisation in pandemic preparedness cohort studies, such as the BEready cohort, should be conducted to determine whether, in the next pandemic, early-stage solidarity in a crisis increases participation. Understanding factors affecting willingness to participate could help develop future strategies to sustain long-term research engagement across diverse populations.

Supporting information

S1 Fig. Distribution of raw data from variables which were dichotomised.

(PDF)

pone.0346420.s001.pdf (104.1KB, pdf)
S2 Fig. Study participants flow chart.

(PDF)

pone.0346420.s002.pdf (32.5KB, pdf)
S1 Table. STROBE checklist for cross-sectional studies.

(PDF)

pone.0346420.s003.pdf (65.4KB, pdf)
S2 Table. Descriptive table of variables included in the analysis.

(PDF)

pone.0346420.s004.pdf (38.3KB, pdf)
S3 Table. Weighting levels and represented households.

(PDF)

pone.0346420.s005.pdf (19.2KB, pdf)
S4 Table. Responders of the survey by household size and language.

(PDF)

pone.0346420.s006.pdf (25.2KB, pdf)
S5 Table. Willingness to participate in a long-term cohort study, unweighted denominators and proportions.

(PDF)

pone.0346420.s007.pdf (39.2KB, pdf)
S6 Table. Sensitivity analysis.

(PDF)

pone.0346420.s008.pdf (42.5KB, pdf)
S7 Table. Reasons to participate or decline participation in a long-term study, unweighted.

(PDF)

pone.0346420.s009.pdf (25KB, pdf)

Acknowledgments

The authors would like to acknowledge Jean-Benoît Rossel for his contribution to data preparation, Christiane Pelzer for her support in data management, and Martin Samuel Wohlfender for his help with data visualisation.

Data Availability

The data from this study are not publicly available because of the risk of identification of an individual participant. Some municipalities in the study area had very few respondents, and the characteristics reported could be combined to identify a person. Data are available upon reasonable request. Researchers interested in accessing the data from this online survey can request it by contacting the project management team at BEready.mcid@unibe.ch or by filling in the request form (https://www.beready.unibe.ch/for_researchers/). De-identified data will be made available to qualified researchers for approved analyses, and access will be granted following review and approval of a study proposal, establishment of a data use and transfer agreement, and successful ethical approval. Restrictions may apply depending on the specific nature of the data requested to ensure participant privacy and compliance with institutional policies. A shared dataset will exclude study participants from municipalities with fewer than 5 respondents. Fees may apply for data preparation and transfer, depending on the nature of the collaboration. We encourage multidisciplinary collaboration on projects that align with the goals of our study, particularly those focused on pandemic preparedness.

Funding Statement

This study was financially supported by the Multidisciplinary Center for Infectious Diseases at the University of Bern in the form of a project grant awarded to AF, MF, and NL (MA21). This study received additional funding from the Multidisciplinary Center for Infectious Diseases at the University of Bern in the form of a grant to the BEready project awarded to NL and GW. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Norton A, Sigfrid L, Aderoba A, Nasir N, Bannister PG, Collinson S, et al. Preparing for a pandemic: highlighting themes for research funding and practice-perspectives from the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R). BMC Med. 2020;18(1):273. doi: 10.1186/s12916-020-01755-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313–9. doi: 10.1016/S0140-6736(20)31304-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Bühler N, Frahsa A, Morand Bourqui R, Von Götz N, Bochud M, Panese F. Between data providers and concerned citizens: Exploring participation in precision public health in Switzerland. Public Underst Sci. 2024;33(1):105–20. doi: 10.1177/09636625231183265 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol. 2007;17(9):643–53. doi: 10.1016/j.annepidem.2007.03.013 [DOI] [PubMed] [Google Scholar]
  • 5.Brall C, Berlin C, Zwahlen M, Ormond KE, Egger M, Vayena E. Public willingness to participate in personalized health research and biobanking: A large-scale Swiss survey. PLoS One. 2021;16(4):e0249141. doi: 10.1371/journal.pone.0249141 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bühler N, Frahsa A, Jaramillo NG, Bourqui RM, Nusslé SG, Zuppinger C, et al. Willingness to participate in a personalized health cohort - insights from the swiss health study pilot phase. BMC Public Health. 2024;24(1):2140. doi: 10.1186/s12889-024-19650-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ipekci AM, Buitrago-Garcia D, Meili KW, Krauer F, Prajapati N, Thapa S, et al. Outbreaks of publications about emerging infectious diseases: the case of SARS-CoV-2 and Zika virus. BMC Med Res Methodol. 2021;21(1):50. doi: 10.1186/s12874-021-01244-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Raj JP, Tomy SK, Jose A, Kashyap A, Kureethara JV, Kallarakal TK. Knowledge and perceptions about clinical research and its ethical conduct among college students from non-science background: a representative nation-wide survey from India. BMJ Public Health. 2024;2(1):e000748. doi: 10.1136/bmjph-2023-000748 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.McKee M, Altmann D, Costello A, Friston K, Haque Z, Khunti K, et al. Open science communication: The first year of the UK’s independent scientific advisory group for emergencies. Health Policy. 2022;126(3):234–44. doi: 10.1016/j.healthpol.2022.01.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Cristea F, Weishaar H, Geurts B, Delamou A, Tan MMJ, Legido-Quigley H, et al. A comparative analysis of experienced uncertainties in relation to risk communication during COVID19: a four-country study. Global Health. 2022;18(1):66. doi: 10.1186/s12992-022-00857-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Heyerdahl LW, Borzykh Y, Lana B, Volkmann A-M, Crusefalk L, Colman E, et al. Outsciencing the scientists: a cross-sectional mixed-methods investigation of public trust in scientists in seven European countries. BMJ Public Health. 2023;1(1):e000280. doi: 10.1136/bmjph-2023-000280 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Klösch B, Hadler M, Reiter-Haas M, Lex E. Polarized opinions on Covid-19 and environmental policy measures. The role of social media use and personal concerns in German-speaking countries. Innovation: The European Journal of Social Science Research. 2023;37(4):941–64. doi: 10.1080/13511610.2023.2201877 [DOI] [Google Scholar]
  • 13.Grimalda G, Murtin F, Pipke D, Putterman L, Sutter M. The politicized pandemic: Ideological polarization and the behavioral response to COVID-19. Eur Econ Rev. 2023;156:104472. doi: 10.1016/j.euroecorev.2023.104472 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Iyengar S, Lelkes Y, Levendusky M, Malhotra N, Westwood SJ. The Origins and Consequences of Affective Polarization in the United States. Annu Rev Polit Sci. 2019;22(1):129–46. doi: 10.1146/annurev-polisci-051117-073034 [DOI] [Google Scholar]
  • 15.Filsinger M, Freitag M. Asymmetric affective polarization regarding COVID-19 vaccination in six European countries. Sci Rep. 2024;14(1):15919. doi: 10.1038/s41598-024-66756-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Gadarian SK, Goodman SW, Pepinsky TB. Partisanship, health behavior, and policy attitudes in the early stages of the COVID-19 pandemic. PLoS One. 2021;16(4):e0249596. doi: 10.1371/journal.pone.0249596 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Schieferdecker D, Joly P, Faas T. Affective polarization between opinion-based groups in a context of low partisan discord: measuring its prevalence and consequences. International Journal of Public Opinion Research. 2024;36(2). doi: 10.1093/ijpor/edae009 [DOI] [Google Scholar]
  • 18.Ipekci AM, Filsinger M, Buitrago-Garcia D, Kobler Betancourt CI, Liwanag HJ, Frahsa A, et al. Polarization and health-related behaviors and outcomes during the COVID-19 pandemic: a systematic review. SSM Popul Health. 2025;33:101891. doi: 10.1016/j.ssmph.2025.101891 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Verberk JDM, de Hoog MLA, Westerhof I, van Goethem S, Lammens C, Ieven G, et al. Transmission of SARS-CoV-2 within households: a remote prospective cohort study in European countries. Eur J Epidemiol. 2022;37(5):549–61. doi: 10.1007/s10654-022-00870-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Alberto-Orlando S, Calderon JL, Leon-Sosa A, Patiño L, Zambrano-Alvarado MN, Pasquel-Villa LD, et al. SARS-CoV-2 transmission from infected owner to household dogs and cats is associated with food sharing. Int J Infect Dis. 2022;122:295–9. doi: 10.1016/j.ijid.2022.05.049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Derqui N, Koycheva A, Zhou J, Pillay TD, Crone MA, Hakki S, et al. Risk factors and vectors for SARS-CoV-2 household transmission: a prospective, longitudinal cohort study. Lancet Microbe. 2023;4(6):e397–408. doi: 10.1016/S2666-5247(23)00069-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Davis MF, Innes GK. The Cat’s in the Bag: Despite Limited Cat-to-Cat Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, One Health Surveillance Efforts Are Needed. J Infect Dis. 2021;223(8):1309–12. doi: 10.1093/infdis/jiab106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Morand Bourqui R, Nusslé SG, von Goetz N, Veys-Takeuchi C, Zuppinger C, Boulez Y, et al. Towards a Swiss health study with human biomonitoring: Learnings from the pilot phase about participation and design. PLoS One. 2023;18(7):e0289181. doi: 10.1371/journal.pone.0289181 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Brall C, Berlin C, Zwahlen M, Vayena E, Egger M, Ormond KE. Public preferences towards data management and governance in Swiss biobanks: results from a nationwide survey. BMJ Open. 2022;12(8):e060844. doi: 10.1136/bmjopen-2022-060844 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Reichmuth ML, Heron L, Riou J, Moser A, Hauser A, Low N, et al. Socio-demographic characteristics associated with COVID-19 vaccination uptake in Switzerland: longitudinal analysis of the CoMix study. BMC Public Health. 2023;23(1):1523. doi: 10.1186/s12889-023-16405-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Issp Research Group. International Social Survey Programme: Social Networks and Social Resources - ISSP 2017. ZA6980. Cologne: GESIS; 2019. doi: 10.4232/1.13322 [DOI] [Google Scholar]
  • 27.Druckman JN, Levendusky MS. What do we measure when we measure affective polarization?. Public Opinion Quarterly. 2019;83(1):114–22. doi: 10.1093/poq/nfz003 [DOI] [Google Scholar]
  • 28.RStudio: Integrated Development Environment for R Version 2024.4.2.764. 2024. [Google Scholar]
  • 29.Lumley T. Survey: analysis of complex survey samples. R package. 2023. doi: 10.18637/jss.v009.i08 [DOI] [Google Scholar]
  • 30.Knol MJ, VanderWeele TJ. Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol. 2012;41(2):514–20. doi: 10.1093/ije/dyr218 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Federal Office of Topography. swissBOUNDARIES3D. 2025. https://www.swisstopo.admin.ch/en/landscape-model-swissboundaries3d
  • 32.Federal Statistical Office. GEOM TK (Geometrische Grundlagen für die thematische Kartografie). Federal Statistical Office (FSO); 2025. https://www.bfs.admin.ch/bfs/de/home/statistiken/regionalstatistik/kartengrundlagen/basisgeometrien.assetdetail.33807959.html [Google Scholar]
  • 33.Rolstad S, Adler J, Rydén A. Response burden and questionnaire length: is shorter better? A review and meta-analysis. Value Health. 2011;14(8):1101–8. doi: 10.1016/j.jval.2011.06.003 [DOI] [PubMed] [Google Scholar]
  • 34.Gabel M, Gooblar J, Roe CM, Selsor NJ, Morris JC. Political ideology, confidence in science, and participation in Alzheimer disease research studies. Alzheimer Dis Assoc Disord. 2018;32(3):179–84. doi: 10.1097/wad.0000000000000244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Onyeaka H, Weber DB, Chido-Amajuoyi O, Muoghalu C, Amonoo HL. The influence of political ideology on clinical trial knowledge, invitation, and participation among adults in the United States. Clin Trials. 2023;20(6):708–13. doi: 10.1177/17407745231178790 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Kim H, Kim HR, Kim S, Kim E, Kim SY, Park H-Y. Public attitudes toward precision medicine: a nationwide survey on developing a national cohort program for citizen participation in the Republic of Korea. Front Genet. 2020;11:283. doi: 10.3389/fgene.2020.00283 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kaufman DJ, Baker R, Milner LC, Devaney S, Hudson KL. A Survey of U.S Adults’ opinions about conduct of a nationwide precision medicine initiative® cohort study of genes and environment. PLoS One. 2016;11(8):e0160461. doi: 10.1371/journal.pone.0160461 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Gaskell G, Gottweis H, Starkbaum J, Gerber MM, Broerse J, Gottweis U, et al. Publics and biobanks: Pan-European diversity and the challenge of responsible innovation. Eur J Hum Genet. 2013;21(1):14–20. doi: 10.1038/ejhg.2012.104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Glass DC, Kelsall HL, Slegers C, Forbes AB, Loff B, Zion D, et al. A telephone survey of factors affecting willingness to participate in health research surveys. BMC Public Health. 2015;15:1017. doi: 10.1186/s12889-015-2350-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Hierro LÁ, Patiño D, Atienza P, Garzón AJ, Cantarero D. The effect of altruism on COVID-19 vaccination rates. Health Econ Rev. 2023;13(1):2. doi: 10.1186/s13561-022-00415-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Dolman AJ, Fraser T, Panagopoulos C, Aldrich DP, Kim D. Opposing views: associations of political polarization, political party affiliation, and social trust with COVID-19 vaccination intent and receipt. J Public Health (Oxf). 2023;45(1):36–9. doi: 10.1093/pubmed/fdab401 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Druckman JN, Klar S, Krupnikov Y, Levendusky M, Ryan JB. Affective polarization, local contexts and public opinion in America. Nat Hum Behav. 2021;5(1):28–38. doi: 10.1038/s41562-020-01012-5 [DOI] [PubMed] [Google Scholar]
  • 43.Torcal M, Thomson ZA. Social trust and affective polarization in Spain (2014–19). Electoral Studies. 2023;81:102582. doi: 10.1016/j.electstud.2023.102582 [DOI] [Google Scholar]
  • 44.Rekker R, Harteveld E. Understanding factual belief polarization: the role of trust, political sophistication, and affective polarization. Acta Polit. 2022;:1–28. doi: 10.1057/s41269-022-00265-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Filsinger M, Freitag M. Divided by vaccination? Evaluating the intergroup conflict between pro- and anti-vaccination groups in the post-pandemic era. Humanit Soc Sci Commun. 2025;12(1). doi: 10.1057/s41599-024-04016-y [DOI] [Google Scholar]

Decision Letter 0

Krzysztof Malarz

20 Jan 2026

-->PONE-D-25-54952-->-->Who would take part in a pandemic preparedness cohort study? The role of vaccine-related affective polarisation: cross-sectional survey-->-->PLOS One

Dear Dr. Low,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 06 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

-->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols....

We look forward to receiving your revised manuscript.

Kind regards,

Krzysztof Malarz, D.Sc., Ph.D., M.Sc.

Academic Editor

PLOS One

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

3. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement.

4. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Before we proceed with your manuscript, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.

Please update your Data Availability statement in the submission form accordingly.

5. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

6.  We note that Figure 1 in your submission contain [map/satellite] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

a. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

8. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

9. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: Yes

**********

-->2. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: Yes

**********

-->3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

**********

-->4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

**********

-->5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: A "literature review" section (immediately before the "Methods" section) should be included to strengthen the work by providing arguments in favor of the variables included in the quantitative analysis. In this regard, the "literature review" section should reference empirical studies on vaccine hesitancy, particularly for COVID-19. A summary table of these studies, categorized by variables influencing vaccine hesitancy and highlighting the most relevant aspects (country and years studied, methodology used, and results), would be very useful.

Likewise, the "comparison with other studies" section should be more comprehensive, including more studies, and a table comparing the results of this work with those of others would also be helpful.

Although the variables included in the quantitative analysis are correct and commonly included in this field of research, it should be discussed why affective polarization is included as a variable and not other political factors that empirical literature has shown to influence attitudes toward the Covid-19 pandemic, such as political ideology, political affiliation, and trust in the government and political institutions. Likewise, the exclusion of a highly likely relevant variable, identified by the authors, namely altruism, should be discussed.

**********

-->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our Privacy Policy..-->..-->

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

-->

PLoS One. 2026 Apr 20;21(4):e0346420. doi: 10.1371/journal.pone.0346420.r002

Author response to Decision Letter 1


12 Mar 2026

We would like to thank the editor and the reviewer for their comments and for the opportunity to revise our manuscript.

We have numbered the editor’s and reviewer’s comments and copied them below. We respond to each comment and describe the changes made in the revised version of the manuscript. We give the line numbers for the location of the revised text in the clean version.

Editor’s comments

1) If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

Authors' response: We have added the financial disclosure statement to the cover letter. We have resubmitted the figure files, following the guidelines.

2) If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future.

Authors' response: The request does not apply to our study, which did not use laboratory-based methods. Nevertheless, we aimed to ensure reproducibility through detailed reporting of the study design, data sources, and analytical methods in the Methods section.

3) Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Authors' response: We would like to thank the editor for this reminder. We have followed the style templates for the text and supplementary material and ensured they are correctly referenced throughout the manuscript.

4) Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

Authors' response: We deleted the additional ethics statement at the end of the manuscript and retained the ethics statement only in the Methods section (page 4, lines 97-99).

5) Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible.

Authors' response: We thank the editor for this request. We appreciate the benefits of publicly available datasets. Due to concerns about the potential for identifying individuals, our data cannot be shared publicly. Please find our Data Availability statement in our response to point 6, below.

6) We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

Please update your Data Availability statement in the submission form accordingly.

Authors' response: Our Data Availability statement has been updated in the submission form, and reads. “The data from this study are not publicly available because of the risk of identification of an individual participant. Some municipalities in the study area had very few respondents, and the characteristics reported could be combined to identify a person. Data are available upon reasonable request. Researchers interested in accessing the data from this online survey can request it by contacting the project management team at BEready.mcid@unibe.ch or by filling in the request form (https://www.beready.unibe.ch/for_researchers/). De-identified data will be made available to qualified researchers for approved analyses, and access will be granted following review and approval of a study proposal, establishment of a data use and transfer agreement, and successful ethical approval. Restrictions may apply depending on the specific nature of the data requested to ensure participant privacy and compliance with institutional policies. A shared dataset will exclude study participants from municipalities with fewer than 5 respondents. Fees may apply for data preparation and transfer, depending on the nature of the collaboration. We encourage multidisciplinary collaboration on projects that align with the goals of our study, particularly those focused on pandemic preparedness.”

7) We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

Authors' response: We confirm that we have written the same grant numbers in the ‘Funding Information’ and ‘Financial Disclosure’ sections. The wording of the Financial Disclosure (p18, lines 381-383) is, “This work was supported by the Multidisciplinary Center for Infectious Diseases, University of Bern (grant number MA21 awarded to AF, MarF, NL and the BEready project, no grant number, awarded to NL, GW).” Please note that this statement lists more than one co-author for each grant. The automated Funding Information section in the submission portal only allows one co-author to be associated with a grant, so this information only includes the first of the authors listed in the statement.

8) We note that Figure 1 in your submission contain [map/satellite] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution.

Authors' response: We appreciate the editors for pointing this out. We have received confirmation from Swiss Federal Office of Public Health, in an email dated 25.02.2026, that, “There are no fees or special authorization for using standard services (Internet). It is important to cite the source (‘Federal Statistical Office, name of statistics + year’ <e.g. ‘Federal Statistical Office, Structural Survey 2017’>).”

Figure 1 was created using two datasets: swissBOUNDARIES3D and the official directory of towns and cities, both published by the Federal Office of Topography swisstopo (swisstopo.admin.ch), and the lakes and rivers 2025_GEOM_TK dataset of Swiss Federal Statistical Office (bfs.admin.ch).

We have added citations to the Federal Office of Topography and the Federal Statistical Office (ref 31, 32) and web addresses to the caption of Figure 1 (page 9, line 214-218).

9) Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Authors' response: We have included captions for our Supporting Information files at the end of our manuscript (page 27, lines 560-569). We have reorganised the supplementary materials to comply with the journal’s requirements and matched all in-text citations accordingly.

10) If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Authors' response: Thank you for this advice. The reviewer did not ask us to cite specific works. The reviewer did ask us to provide additional citations to support statements in the Introduction and Discussion, Comparison with other studies sections. We agreed with the comments and chose relevant references ourselves. In the Introduction, we added one reference (number 18). In the discussion, we added two references (numbers 38 and 39).

11) Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Authors' response: We have verified that our reference list contains no retracted articles. Our response to the reviewer includes all additional references, and the location in the text where they are cited.

Reviewer’s comments

1) A "literature review" section (immediately before the "Methods" section) should be included to strengthen the work by providing arguments in favor of the variables included in the quantitative analysis. In this regard, the "literature review" section should reference empirical studies on vaccine hesitancy, particularly for COVID-19. A summary table of these studies, categorized by variables influencing vaccine hesitancy and highlighting the most relevant aspects (country and years studied, methodology used, and results), would be very useful.

Authors' response: Thank you for the feedback about the need for a relevant literature review in the Introduction. We appreciate the opportunity to clarify the scope of our work. We apologise if we gave the reviewer the wrong impression about the subject of our study. To clarify, we have not used the words ‘vaccine hesitancy’ in any part of the manuscript. Our paper is about willingness to take part in research about pandemic preparedness – and how this might be affected by people’s feelings and opinions. We assessed feelings using a measure of affective polarisation in relation to views about COVID-19 vaccination – both positive and negative. Our review of the literature in the Introduction therefore included: studies about factors associated with willingness to participate in research before the COVID-19 pandemic (refs 4-6, cited p3); reasons why the COVID-19 pandemic might have affected willingness to participate (refs 7-11, cited p3); and the relevance of polarisation and affective polarisation (refs 12-17, cited p4). To address the reviewer’s comment, we made changes to:

- Abstract: we have made the subject of the study clearer at the start of the Abstract, “Willingness to participate in research is associated with multiple factors. Little is known about the role of people’s feelings, especially in the aftermath of the COVID-19 pandemic.” (page 2, lines 21-24).

- Introduction: we added a new reference, which is a systematic review about affective polarisation related to COVID-19 vaccination “Whilst affective polarisation was first defined and studied in the United States of America to understand [14], the COVID-19 pandemic revealed associations between affective polarisation and health behaviours such as COVID-19 vaccination uptake, adherence to pandemic countermeasures or anxiety about COVID-19 [14-18]” (page 3, line 80, ref 18).

We have followed the submission guidelines of the journal to provide “a brief review of the key literature.” Given that our literature review covers a range of different issues to put the study into context, we did not think it appropriate to tabulate these studies.

2) Likewise, the "comparison with other studies" section should be more comprehensive, including more studies, and a table comparing the results of this work with those of others would also be helpful.

Authors' response: We thank the reviewer for this constructive suggestion. We have expanded the "Comparison with other studies" section. We added two relevant studies (refs 38, 39), giving examples of other types of population-based health research (page 16, line 308-312), “Similarly, a large European survey involving 32 countries found that 53.3% of respondents were willing to provide personal information to a biobank [38]. In Australia, a telephone survey found that 61% of respondents were willing to participate in health research in general, with willingness increasing when specific information about the study was provided [39].” We believe that the six cited studies provide a concise but sufficient narrative overview of the current literature.

Regarding the suggested table, we would like to retain the description within the narrative of the text. These studies are examples of other types of research about willingness to participate. We feel that a table with detailed study-level information might give the impression of a comprehensive systematic literature search, which is beyond the scope of our study. We believe that introducing a table with a large amount of additional data at this stage might confuse the reader, potentially distracting from the primary focus of our study.

3) Although the variables included in the quantitative analysis are correct and commonly included in this field of research, it should be discussed why affective polarization is included as a variable and not other political factors that empirical literature has shown to influence attitudes toward the Covid-19 pandemic, such as political ideology, political affiliation, and trust in the government and political institutions.

Authors' response: We thank the reviewer for this comment and for the opportunity to articulate our choices more clearly. We agree that there is already empirical literature about political factors. We now acknowledge this explicitly in the Introduction (page 3-4, lines 72-74), “Political polarisation, according to ideology, partisan affiliation or trust in political institutions, has characterised responses to many aspects of COVID-19 prevention [12-13].”

We found a gap in the evidence about the role of affective polarisation, however. We have revised the introduction to make this point more clearly (page 4, lines 80-84), “Measures of people’s feelings about public health measures such as COVID-19 vaccination, and how they view others, are more proximate to health-associated behaviours than partisan or ideological differences. Whether affective polarisation is associated with willingness to take part in research about pandemics more generally is not well understood.”

In practice, the number of questions permitted in the questionnaire was restricted. We acknowledge this limitation in the Discussion, Strengths and limitations, including three new references (33, 34, 35) (page 16, lines 289-293), “Third, the number of questions in the survey was restricted since a lengthy questionnaire might have decreased the response rate [33]. Whilst there is evidence that political ideology and trust in government institutions are associated with an individual’s willingness to participate in scientific research [34, 35], we were not able to include questions about a broader range of political variables.”

4) Likewise, the exclusion of a highly likely relevant variable, identified by the authors, namely altruism, should be discussed.

Authors' response: We thank the reviewer for raising this important point. We agree that altruism is indeed a relevant factor in willingness to participate in research. Unfortunately, it was not measured as a standalone variable in our survey and therefore coul

Attachment

Submitted filename: PLOSOne Reviewer comments_formatted_offline.docx

pone.0346420.s011.docx (104.3KB, docx)

Decision Letter 1

Angelo Moretti

19 Mar 2026

Who would take part in a pandemic preparedness cohort study? The role of vaccine-related affective polarisation: cross-sectional survey

PONE-D-25-54952R1

Dear Dr. Low,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support....

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Angelo Moretti, Ph.D.

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #1: All comments have been addressed

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: Yes

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: Yes

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: (No Response)

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our Privacy Policy..-->..-->

Reviewer #1: Yes:Pedro Atienza MonteroPedro Atienza MonteroPedro Atienza MonteroPedro Atienza Montero

**********

Acceptance letter

Angelo Moretti

PONE-D-25-54952R1

PLOS One

Dear Dr. Low,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Angelo Moretti

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Distribution of raw data from variables which were dichotomised.

    (PDF)

    pone.0346420.s001.pdf (104.1KB, pdf)
    S2 Fig. Study participants flow chart.

    (PDF)

    pone.0346420.s002.pdf (32.5KB, pdf)
    S1 Table. STROBE checklist for cross-sectional studies.

    (PDF)

    pone.0346420.s003.pdf (65.4KB, pdf)
    S2 Table. Descriptive table of variables included in the analysis.

    (PDF)

    pone.0346420.s004.pdf (38.3KB, pdf)
    S3 Table. Weighting levels and represented households.

    (PDF)

    pone.0346420.s005.pdf (19.2KB, pdf)
    S4 Table. Responders of the survey by household size and language.

    (PDF)

    pone.0346420.s006.pdf (25.2KB, pdf)
    S5 Table. Willingness to participate in a long-term cohort study, unweighted denominators and proportions.

    (PDF)

    pone.0346420.s007.pdf (39.2KB, pdf)
    S6 Table. Sensitivity analysis.

    (PDF)

    pone.0346420.s008.pdf (42.5KB, pdf)
    S7 Table. Reasons to participate or decline participation in a long-term study, unweighted.

    (PDF)

    pone.0346420.s009.pdf (25KB, pdf)
    Attachment

    Submitted filename: PLOSOne Reviewer comments_formatted_offline.docx

    pone.0346420.s011.docx (104.3KB, docx)

    Data Availability Statement

    The data from this study are not publicly available because of the risk of identification of an individual participant. Some municipalities in the study area had very few respondents, and the characteristics reported could be combined to identify a person. Data are available upon reasonable request. Researchers interested in accessing the data from this online survey can request it by contacting the project management team at BEready.mcid@unibe.ch or by filling in the request form (https://www.beready.unibe.ch/for_researchers/). De-identified data will be made available to qualified researchers for approved analyses, and access will be granted following review and approval of a study proposal, establishment of a data use and transfer agreement, and successful ethical approval. Restrictions may apply depending on the specific nature of the data requested to ensure participant privacy and compliance with institutional policies. A shared dataset will exclude study participants from municipalities with fewer than 5 respondents. Fees may apply for data preparation and transfer, depending on the nature of the collaboration. We encourage multidisciplinary collaboration on projects that align with the goals of our study, particularly those focused on pandemic preparedness.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES